drugset
drugset / Trial / NCT03964038

A Study to Assess the Relative Bioavailability of Gilteritinib Following a Single Dose of Gilteritinib Mini-tablet Oral Suspension and Gilteritinib Mini-tablets Compared to a Single Dose of Gilteritinib Tablet in Healthy Subjects

NCT03964038 ↗

Phase 1 Completed 48 enrolled Astellas Pharma Global Development, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the relative bioavailability as well as the safety and tolerability of single doses of gilteritinib mini-tablets oral suspension and gilteritinib mini tablets compared to gilteritinib tablets under fasting conditions in healthy male and female participants.

Timeline

Start
2019-05-21
Primary completion
2019-07-02
Completion
2019-07-16

Drugs

EvaluationDrugModalityDoseRoute
Comparator Gilteritinib Small molecule — Oral

Indications

No indication recorded.